Compare Crowdstrike Holdings Inc (CRWD) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crowdstrike Holdings Inc vs Merck & Co., Inc. — how do they compare? Crowdstrike Holdings Inc trades at $213.81 (market cap $214.58B), while Merck & Co., Inc. trades at $124.34 (market cap $298.31B). The key difference: Merck & Co., Inc. is the larger of the two by market cap, and Merck & Co., Inc. pays a 2.82% dividend while Crowdstrike Holdings Inc pays none. Which is the better fit depends on your goals.
| CRWD | MRK | |
|---|---|---|
Market Cap | $214.58B | $298.31B |
Sector | Technology | Health |
52-Week High | $210.73 | $129.52 |
52-Week Low | $87.56 | $77.60 |
Enterprise Value | $210.85B | $341.72B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CrowdStrike (CRWD) trades at $187.91, up 0.39% on the day, with a bullish technical signal and strong support near $185. The stock has delivered three consecutive quarterly EPS beats, with Q2 2026 expected at $0.29. Revenue growth remains robust, rising from $1.5B in 2022 to $4.0B in 2025, though net margins are slightly negative. A recent 4-for-1 stock split on July 2, 2026, has increased accessibility amid heightened investor interest in AI-driven cybersecurity.
Outlook is supported by solid cash flow growth and dominant market positioning, but premium valuations (P/E 765, P/S 37) pose risks if growth decelerates. Analyst consensus is strongly bullish with a $184.39 price target, though competitive pressures and execution challenges remain key watchpoints for sustained upside.
Merck (MRK) trades at $124.03, up 0.4% today, with a bullish technical signal from moving averages and a consensus analyst price target of $137.30. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of -$1.28 beating expectations, and maintains robust profitability with a net income margin of 13.59%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include rising debt levels and patent expirations. Institutional buying activity supports bullish sentiment, though investors should monitor execution risks and macroeconomic pressures affecting the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crowdstrike Holdings Inc
CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
